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Abstract  
Background: Optimal prescribing of secondary prevention medications after acute coronary syndrome (ACS) events has been shown to 
reduce morbidity and mortality. However, it is unknown whether these medications are optimally prescribed at discharge from acute 
care in Iraq. 
Objective: To evaluate whether patients with ACS received optimal secondary prevention medications: antiplatelets, statins, 
angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARBs), and beta-blockers at discharge from a 
cardiology unit, and to assess whether statins, ACEI/ARBs and beta-blockers were prescribed at target doses based on the American 
Heart Association/American College of Cardiology (AHA/ACC) guidelines. 
Methods: Observational retrospective cross-sectional study of patients with ACS admitted to a hospital in Baghdad and survived to 
discharge between May 2016 and January 2017. Patient-level data and secondary prevention medications at discharge were extracted 
from routine medical records. Optimal dosing was defined as ≥75%, moderate dosing as 50–74%, and low dosing as <50% of the target 
dose.  
Results:  45.6% (200/439) of eligible patients were included in the study who were aged 25 to 90 years (mean 57.8 years) with 78.0% 
(156/200) being male. Of those included, 84.5% had a myocardial infarction and 15.5% unstable angina, and the length of hospital stay 
ranged from 1 to 29 days (median 4 days).  In total, 53.5% of patients were prescribed all five secondary prevention medications at 
discharge, and after accounting for contraindications, 60.0% were treated according to AHA/ACC guidelines. The prescription rate of 
dual antiplatelet therapy, statins, ACEI/ARBs and beta-blockers was 92.5%, 94.5%, 69.5% and 87.0% respectively. Hypertension, 
diabetes mellitus and the prescription of oral nitrates were associated with the prescription of optimal secondary prevention therapy. 
Although 80.9% of patients were prescribed target doses of antiplatelets and statins, only 12.2% and 9.2% were prescribed target 
doses of ACEI/ARBs, and beta-blockers respectively.  
Conclusions: Approximately one in two patients received the recommended secondary prevention therapy. However, only a minority 
of patients were prescribed optimal doses of ACEI/ARBs and beta-blockers, in line with guidance. Quality improvement strategies 
should be implemented, which may include greater involvement of pharmacists within the cardiology multidisciplinary team. 
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INTRODUCTION 
Cardiovascular disease is the leading cause of morbidity 
and mortality globally.1 In Iraq, cardiovascular disease is the 
primary cause of hospitalisations and accounts for 33% of 
total deaths.2,3 Acute coronary syndrome (ACS) is an 
umbrella term referring to any group of clinical signs and 
symptoms consistent with acute myocardial ischemia.4 ACS 
includes unstable angina, non–ST-segment elevation 
myocardial infarction (NSTEMI), and ST-segment elevation 
myocardial infarction (STEMI), all of which are life-
threatening events and major causes of hospitalisations, 
rising healthcare costs, morbidity, and mortality.5,6 
In the acute phase of ACS, aggressive management is 
required to improve prognosis.7 Patients surviving ACS are 
at a high-risk of subsequent cardiovascular events and 
death:7-9 one in four men and one in five women will die 
within 12 months of an ACS event.7 Fortunately, a better 
understanding of the pathophysiological mechanisms 
involved in ACS has allowed the development of invasive 
interventions such as percutaneous coronary intervention 
and coronary artery bypass grafting and non-invasive 
secondary prevention medications, including dual 
antiplatelet therapy, angiotensin-converting enzyme 
inhibitors/angiotensin II receptor blockers (ACE/ARBs), 
beta-blockers, and statins.5,9,10 
Regular use and optimal dosing with secondary prevention 
medications improve quality of life and survival; reducing 
cardiovascular events and mortality by up to 80%.11,12 
Therefore, the American Heart Association/American 
College of Cardiology (AHA/ACC) guidelines, which are used 
as national guidance in Iraq, recommend prescribing 
secondary prevention medications before discharge to all 
patients without contraindications.13,14  
Unfortunately, the literature indicates that secondary 
prevention medications are inconsistently prescribed, 
commonly at suboptimal doses, and poorly adhered to by 
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patients.4,10,11,15,16 Statins can be initiated at optimal doses, 
while ACE/ARBs and beta-blockers need to be titrated to 
the optimal dose.11 Although optimising doses before 
discharge is recommended, some patients may have 
contraindications or be unable to tolerate dose titration 
due to common factors such as hypotension, bradycardia, 
or worsening renal function.11,13,17 However, by ensuring 
patients are prescribed optimal secondary prevention 
medications at discharge, physicians can increase the 
likelihood of adherence to these medicines post-discharge 
and optimise long-term outcomes.9,11 
Studies evaluating current practices in Iraq against 
AHA/ACC guidelines are sparse. Therefore, this study’s 
objectives were (1) to evaluate whether ACS patients 
receive optimal secondary prevention medications, 
consisting of dual antiplatelet therapy, statins, ACE/ARBs 
and beta-blockers at discharge from a cardiology unit at a 
government teaching hospital in Baghdad, as per AHA/ACC 
guidelines and (2) to assess whether statins, ACEI/ARBs and 
beta-blockers were prescribed at optimal doses to these 
patients.13,14 
 
METHODS 
Ethics approval 
This study received ethical approval from the College of 
Pharmacy at the University of Mustansiriyah. In addition, 
the hospital gave approval for patient-level data to be 
collected from medical records. All patient-level data were 
anonymised prior to analysis to ensure patient 
confidentiality. 
Study design and setting 
This study used an observational retrospective cross-
sectional design, applied to routinely collected patient-level 
data. The study was conducted within a major teaching 
hospital in Baghdad, Iraq’s largest city, which provides free 
state-funded health care and delivers ACS care to 
approximately 700 patients per year. 
Participant identification and data collection 
Patients were eligible for this study if they were admitted 
to the study site and survived an ACS event from May 2016 
to January 2017. For the purposes of the study an ACS 
event was defined as incident STEMI, NSTEMI, or unstable 
angina recorded in the medical notes of an admitted 
patient, plus clinical signs/symptoms of chest pain 
associated with electrocardiography changes and/or 
troponin level elevation. Patients were excluded from the 
study if they left against medical advice, died or were 
transferred to another hospital.  If patients were admitted 
twice during the study, only their first admission was 
included. Given the descriptive nature of the study, 
resource constrains and the incidence rate of ACS within 
the site, a sample size of 200 patients was deemed 
appropriate. These patients were identified via 
convenience sampling by hospital administrative staff who 
screened medical records for incident ACS until 200 
patients were included. The sampling methodology was not 
random and did not include consecutive patients. 
Following identification, retrospective patient-level data 
were collected from written medical records, from October 
2016 to February 2017, by one experienced clinical 
Table 1. Demographic and clinical characteristics of the study population 
Characteristics 
All patients 
n=200 (%) 
Five medications received 
n=107 (53%) 
Five medications not received 
n=93 (46%) 
Univariate 
p-value 
Mean age, years (range) 57.8 (25-90) 58.1 (25-90) 57.4 (28-85) 0.677 
Gender    0.866 
Male 156 (78.0) 84 (78.5) 72 (77.4)  
Female 44 (22.0) 23 (21.5) 21 (22.6)  
Type of ACS    0.509 
STEM 134 (67.0) 68 (63.5) 66 (70.9)  
NSTEMI 35 (17.5) 20 (18.7) 15 (16.1)  
Unstable angina 31 (15.5) 19 (17.8) 12 (12.9)  
Past medical history     
Hypertension 117 (58.5) 70 (65.4) 47 (50.5) 0.044 
Diabetes mellitus 77 (38.5) 32 (29.9) 45 (48.4) 0.009 
Ischemic heart disease 63 (31.5) 38 (35.5) 25 (26.9) 0.223 
Heart failure or LVSD 12 (6.0) 8 (7.5) 4 (4.3) 0.388 
Cerebrovascular accident 10 (5.0) 5 (4.7) 5 (5.4) 1 
Peptic ulcer 6 (3.0) 2 (1.9) 4 (4.3) 0.420 
Number of Co-morbidities    0.542 
0 37 (18.5) 17 (15.9) 20 (21.5)  
  1 70 (35.0) 40 (37.4) 30 (32.3)  
  ≥2 93 (46.5) 50 (46.7) 43 (46.2)  
Other Medications     
Diuretics 40 (20.0) 22 (20.6) 18 (19.4) 0.861 
Nitrates 32 (16.0) 24 (22.4) 8 (8.6) 0.011 
Calcium channel blockers 11 (5.5) 5 (4.7) 6 (6.5) 0.758 
Vitals at Discharge     
Mean SBP, mmHg (range) 123.8 (85-180) 125.8 (92-180) 121.5 (85-180) 0.114 
Mean DBP, mmHg (range 73.3 (50-104) 74.9 (50-104) 71.6 (50-90) 0.036 
Mean HR, bpm (range) 78.3 (46-120) 78.2 (46-120) 78.4 (46-110) 0.906 
Mean length of hospital stay, days  (range)  4.3 (1-29) 4.1  (1-19) 4.6 (1-29) 0.380 
STEMI: ST-segment elevation myocardial infarction; NSTEMI: non–ST-segment elevation myocardial infarction; SBP: systolic blood pressure; DBP: 
diastolic blood pressure; HR: heart rate; bpm: beats per minute. 
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pharmacist using a standardised data collection form. Data 
included: age, gender, primary diagnosis, past medical 
history, blood pressure at discharge, heart rate at 
discharge, and prescribed drugs and doses on the day of 
discharge. The hospital inpatient prescription on the day of 
discharge was used to confirm the discharge medication, as 
the formal discharge prescription is not permanently stored 
in the patient’s records, but given to the patient at 
discharge. 
Measurement of outcomes 
The primary endpoint was the number of patients 
prescribed appropriate secondary prevention medications 
at discharge. For the purpose of the study, appropriate 
secondary prevention medications were defined as being 
prescribed dual antiplatelet therapy, statin, ACEI/ARB and 
beta-blocker at discharge in accordance with AHA/ACC 
guidance. When patients had a clinical contraindication, in 
accordance with AHA/ACC guidance, precluding the use of 
one or more medications this was also counted as 
appropriate secondary prevention therapy.13,14 
Secondary endpoints were the number of patients 
receiving optimal doses of ACEI/ARBs, beta-blockers, and 
high-intensity statins at discharge.13,14 The following daily 
target doses were used: beta-blockers (metoprolol 200 mg; 
atenolol 100 mg; carvedilol 50 mg; and bisoprolol 10 mg) 
ACEI/ARBs (captopril 150 mg; enalapril 20 mg; lisinopril 10 
mg; ramipril 10 mg; valsartan 320 mg; losartan 150 mg; and 
candesartan 32 mg) and high-intensity statins (atorvastatin 
80 mg or rosuvastatin 20 mg or 40 mg).15,16,18  A dose 
intensity ranking was then used to define optimal doses as 
low (<50% of target dose), medium (50–74%) and high 
(≥75%).11 Systolic blood pressure and heart rate were 
evaluated for patients to determine whether low systolic 
blood pressure prevented dose optimization in low dose 
users of ACEI/ARBs and beta-blockers. 
Statistical analysis 
Descriptive statistics were used to describe patient 
demographics, the proportion and percentage of patients 
receiving secondary prevention medications, and target 
doses at discharge. Pearson's chi-squared test, Fisher’s 
exact test (categorical variables) and the independent t-test 
(continuous variables) were used as appropriate, 
depending on the data, to test for associations between 
demographic characteristics and the use of medications at 
discharge. Based on the results of the above tests, variables 
with statistical significance associated with receiving all five 
medications at discharge were also subjected to binary 
logistic regression in order to determine independent 
predictors associated with receiving all five medications at 
discharge. Data were analysed using SPSS version 26.0 
(INM Corp, Chicago, IL) and two-tailed p- values less than 
0.05 were used to indicate statistical significance. 
 
RESULTS  
Prescription of secondary prevention medications 
During the study period, 522 patients were admitted with 
ACS. Of these, 439 (84.1%) were eligible for the study, and 
45.6% (200/439) were included. Of the 83 (15.9 %) 
ineligible patients, 39 left against medical advice, 31 died, 
and 13 transferred to another hospital. 
Included patients varied in age from 25 to 90 years old 
(mean 57.8) and 78.0% (n=156) were male, with 84.5%  
(n=169) having a primary diagnosis of myocardial infarction 
and 15.5% (n=31) having unstable angina. Baseline cardiac 
risk factors included; 58.5% (n=117) hypertension; 38.5% 
(n=77) diabetes and 31.5% (n=63) with a previous history of 
ischemic heart disease. The median duration of hospital 
stay was 4 days, (range 1 to 29 days); see Table 1.    
In total, 53.5% (n=107) of patients were prescribed all five 
medications, see Table 2. Thirteen additional patients had 
contraindications for one or more secondary prevention 
medications. Therefore, when valid contraindications were 
accounted for, 60.0% (n=120) of patients were assessed 
against guidelines to be prescribed appropriate secondary 
prevention therapy. Most commonly prescribed 
medications were: clopidogrel 98.0% (n=196), statins 94.5% 
(n=189) (52.4% atorvastatin, 47.6% rosuvastatin), aspirin 
93.5% (n=187), dual antiplatelet therapy 92.5% (n=185) 
(aspirin and clopidogrel in all cases), beta-blockers 87.0% 
(n=174) (78.2% metoprolol, 14.4% carvedilol, 5.7% 
bisoprolol and 1.7% atenolol) and ACEI/ARBs  69.5% 
(n=139) (82.7% captopril, 5.0% enalapril, 2.2% lisinopril, 
0.7% ramipril, 5.8 % candesartan, 2.2% valsartan and 1.4% 
losartan). No patients were co-prescribed ACEI and ARB. 
There was statistically significant association between the 
use of all five medications and mean diastolic blood 
pressure. In addition, there was a significant association 
between ACE/ARBs prescribing and hypertension, diabetes 
mellitus and being discharged on oral nitrate, see Table 3. 
Binary logistic regression indicated that comorbidities such 
as hypertension (odd ratio=2.05, 95%CI 1.11 to 3.79; 
p=0.022) and diabetes mellitus (odd ratio=0.42, 95%CI 0.23 
to 0.78; p=0.006) as well as oral nitrate prescription (odd 
ratio=2.95 95%CI 1.22 to 7.12; p=0.016) were associated 
with receiving all five medications at discharge. 
Table 2. Guideline adherence and target dosing for secondary prevention medications 
Prescribed medications 
Guideline Adherence Target Dosing Range 
On Therapy 
n (%) 
Appropriate secondary prevention therapy
a
 
n (%) 
Low 
n (%
b
) 
Medium 
n (%
 b
) 
High 
n (%
 b
) 
Clopidogrel 196 (98.0) 196 (98.0) N/A N/A 196 (100) 
Aspirin  187 (93.5) 190 (95.0) N/A N/A 187 (100) 
Dual antiplatelet therapy 185 (92.5) 188 (94.0) N/A N/A 185 (100) 
Statin 189 (94.5) 189 (94.5) N/A 36 (19.1) 153 (80.9) 
Beta-blockers 174 (87.0) 182 (91.0) 76 (43.7) 82 (47.1) 16 (9.2) 
ACE/ARBs 139 (69.5) 147 (73.5) 98 (70.5) 24 (17.3) 17 (12.2) 
All five medications 107 (53.5) 120 (60.0) NA N/A 2 (1.9 ) 
a
 On medication or valid contraindication 
b
 Of those on medication 
Nassr OA, Forsyth P, Johnson CF. Evaluation of discharge prescriptions for secondary prevention in patients with acute coronary 
syndromes in Iraq. Pharmacy Practice 2019 Jan-Mar;17(1):1372.  
https://doi.org/10.18549/PharmPract.2019.1.1372 
 
www.pharmacypractice.org (eISSN: 1886-3655 ISSN: 1885-642X) 4 
Dosing of secondary prevention medications 
Regarding optimal dosing, all patients prescribed 
antiplatelets received optimal doses: aspirin 100 mg and/or 
clopidogrel 75 mg daily.  Of the 94.5% of patients (n=189) 
who received a statin, 80.9% (n=153) were prescribed a 
high-intensity statin. Of the 69.5% of patients (n=139) that 
received ACEI/ARBs, 12.2% (n=17) were prescribed a dose 
in the high target range. Of the 87.0% of patients (n=174) 
that received a beta-blocker, 9.2% (n=16) were prescribed a 
dose in the high target range. (Table 2). Of the 53.5% of 
patients (n=107) prescribed all five medication classes, only 
1.9% patients (n=2) were prescribed all five medication 
classes within the high target dose range.   
The number of patients who remained on low or moderate 
dose of beta-blockers (n=158) and were affected by 
marginal hemodynamics was low; 4.4% (7/158) had a heart 
rate >60 beats per minutes (bpm) and were therefore not 
candidates for titration to target dose whereas 83.5% 
(132/158) had a heart rate of ≥70 bpm. Only 20.9 % 
(33/158) had a systolic blood pressure reading >110 mmHg, 
24.1% (38/158) had blood pressure level between 110-119 
mmHg and 55.1% (87/158) had blood pressure ≥120mmHg. 
Of the patients who remained on low or moderate doses of  
ACEI/ARBs (n=122), only 17.2% (21/122) had blood 
pressure >110 mmHg and were not considered for dose up-
titration whereas 18.9% (23/122) had blood pressure 
reading between 110-119 mmHg with the majority 63.9% 
(78/122) had blood pressure over 120 mmHg. 
 
DISCUSSION 
This observational study is the first study to deliver a 
detailed assessment of prescribing, including optimal 
dosing, of secondary prevention medications at hospital 
discharge in Iraq. Just over half (53.5%) of patients 
admitted with ACS were prescribed all five secondary 
prevention medications at discharge, as advised in 
AHA/ACC guidelines and the guideline adherence rate was 
60% after accounting for valid contraindications.13,14 The 
highest adherence was for clopidogrel and the lowest for 
ACEI/ARBs. While an overwhelming majority of patients 
were prescribed target antiplatelet and high-intensity statin 
doses, only a minority were prescribed optimal ACEI/ARB 
and beta-blocker doses (12.2% and 9.2%, respectively). 
This study’s main finding that 60% of patients were treated 
according to the ACC/AHA guidelines when accounting for 
contraindications is comparable with previous studies from 
Western countries which found 69.1% adherence to 
guidance.8 and from within the Middle East, which showed 
62.9% adherence.
5
 The prescribing of individual 
medications within this study is also broadly similar to or 
higher than studies from Western countries.8,9,19 
Hypertension, diabetes mellitus and being on oral nitrates 
were associated with receiving all five medications at 
discharge as observed in previous studies.8,20 Although 
these findings show that Iraqi care is in line with current 
international benchmarks, physicians can still improve the 
prescribing of these cost-effective medications and thereby 
reduce further avoidable morbidity and mortality.8,10 
Early initiation of intensive statin therapy following ACS 
contributes to improved long-term survival.21 This study 
showed a high rate of prescribing statins, i.e., 94.5% of 
patients, with 80.9% of those receiving a high-intensity 
statin. However, almost half of the patients received 
rosuvastatin, for which a-priori mortality and morbidity 
evidence to support its use in secondary prevention is 
currently inadequate compared to atorvastatin.13,17,21,22 In 
addition, only 63.6% of patients prescribed atorvastatin 
received a dose of 80 mg while 100% of those prescribed 
rosuvastatin received a dose ≥20 mg. A preference for 
prescribing rosuvastatin is not in line with Western 
practice, where almost all patients receive atorvastatin 
rather than rosuvastatin at discharge.8,23 The reasons for 
the high use of rosuvastatin in this study are unclear. 
The ACC/AHA Guidelines indicate that all eligible patients 
should receive ACE/ARBs before discharge unless 
contraindicated.13,14 However, as with previous Dutch and 
Malaysian studies, ACE/ARBs were the least prescribed 
medications, and more likely to be missed, with only 69.5% 
of patients receiving them, and only 4.0% of patients 
having a valid contraindication.8,24  In certain patient 
groups, such as those with heart failure, hypertension, or 
diabetes, these medications have a strong evidence base 
(class A, level of evidence A) and are vitally important in 
reducing morbidity and mortality, and are commonly used 
as a quality performance measure.13,14 In this study, there 
were univariate associations between ACEI/ARB prescribing 
and target dosing and a history of diabetes or hypertension 
(see Table 3). A past medical history of heart failure could 
not be tested due to the small numbers involved. The 
primary reason for favoring captopril during admission is 
not entirely clear but may include the fact that it is short 
acting and avoids a longer period of hypotension caused by 
longer acting ACEI/ARBs. Within the institution, captopril is 
also favored due to its generic nature, consistent supply 
from wholesalers and low acquisition cost which eases 
economic burden on the patient and hospital.   
The percentage of patients prescribed ACEI/ARBs (12.2%) 
and beta-blockers (9.2%) in the high target range was lower 
than previous studies where 1 in 3 patients received 
optimal doses.11 However, our findings are consistent with 
a French study and better than a Danish study which 
reported that 33.0% of ACE/ARBs and 8.0% of beta-blocker 
users respectively received ≥50.0% of the target doses 
(moderate to high dose range).15,16 Previous literature 
demonstrates that optimal ACEI dosing is achievable with 
upward titration over 3 days for patients admitted with 
ACS. However, these patients were not receiving beta-
blocker titration at the same time, and so this reflects the 
challenges of routine clinical practice compared to single 
drug-disease trial models.25  
Table 3. Univariate statistical significance of receiving secondary prevention therapy by clinical characteristics 
Clinical characteristics Aspirin Clopidogrel Statins Beta-blockers ACEI/ARBs 
Hypertension  0.725 1 0.531 0.736 0.017 
Diabetes mellitus 0.554 1 0.341 0.196 0.040 
Receiving oral nitrate  0.697 1 0.218 1 0.016 
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Possible explanations for suboptimal dosing are unknown 
but may include a lack of physician knowledge regarding 
target dosing, marginal clinical parameters such as 
hypotension, worsening renal function, and/or that 
prescribers do not consider dose optimisation a priority 
during a short hospital stay (median hospital stay in this 
study was 4 days).11 However, only 4.4% of low and 
moderate dose beta-blocker users had a heart rate of less 
than 60 bpm and only 17.2% (21/122) and 20.9% (33/158) 
of ACEI/ARB and beta-blocker users respectively had a 
blood pressure reading of less than 110 mmHg and were 
therefore not able to titrate to the target dose.  This is in 
line with a US study which reported that only 19.0% of 
eligible patients were discharged on goal doses of beta-
blockers and that 34.0% and 45.0% of those prescribed low 
and moderate doses of ACEI/ARBs respectively at discharge 
had a blood pressure ≥120 mmHg.11 Thus, it is unlikely that 
marginal hemodynamic results prevented dose 
optimization during admission. In such cases, given the 
nature of the Iraqi healthcare system and with the benefit 
of secondary prevention medications being dose-related, 
every effort should be made to optimise doses during the 
inpatient stay or the importance of post-discharge 
titrations to optimal doses should be explained to the 
patient. 
Strengths  
This is the first study to evaluate the in-depth prescribing of 
secondary prevention medications, including dose, after 
ACS in Iraq.  The cohort represents nearly half of the 
eligible patients admitted during the study period and 
hence should be representative of hospital admissions. The 
data were collected by one experienced clinical pharmacist, 
thus limiting inter-researcher variation. Utilizing routine 
medical records overcomes coding issues associated with 
electronic databases and thus, represents a more accurate 
method for data collection.9,20 Moreover, measuring 
guideline adherence for prescribing optimal doses of 
secondary prevention medications overcomes the 
limitation of previous studies.8,20    
Limitations 
As a retrospective study using routinely collected patient-
level data, the study was limited by data accuracy due to 
record-keeping errors, such as undocumented 
contraindications or medication intolerance.  However, the 
clinical pharmacist who collected the data was aware of 
such potential issues and took time to identify 
contraindications and drug allergies during data collection. 
The sampling methodology was not random and did not 
include consecutive patients, which may introduce bias; 
however, the final cohort constituted 45.6% of eligible 
patients during the study period. The presence of full 
echocardiogram and angiography results, incorporating 
post-infarct left ventricular function and the presence and 
burden of residual coronary heart disease, was also 
unavailable. These results may have influenced physician 
decisions around ACE/ARB and beta-blocker prescribing. As 
this study was conducted in a single hospital, it may not 
reflect wider Iraqi practice.  Finally, given the cross-
sectional nature of the study data on post-discharge 
mortality rates, new hospitalizations and disease 
recurrence were not available and would require further 
research. 
Policy, practice and research implications 
This study concentrated on the short-term prescription of 
secondary prevention medications during the discharge 
phase of ACS hospital care. To date, there is no published 
literature on the post-discharge phase of Iraqi ACS care. 
Standard Iraqi post-discharge care, usually involves a 
patient visiting a cardiologist either in a state-funded or in a 
private primary care facility. In such settings, the prescriber 
is expected to optimise ACEI/ARB and beta-blocker doses 
to achieve the target dose based on the patient’s tolerance 
and hemodynamics. The cost of medication and certain 
aspects of healthcare is however a potential barrier to the 
long-term persistence with therapy. In addition, the quality 
of care in the public sector is suboptimal due to the heavy 
workload experienced by physicians.26 Thus, every attempt 
should be made to titrate the doses during hospital 
admission, whenever possible.13,17 
The exact individual reasons for 40.0% of patients not being 
treated according to guidelines are unknown. The 
regression analysis showed that patients with hypertension 
or those using oral nitrates were more likely to be treated 
in accordance with guidelines. Both of these cohorts 
represent ‘higher’ risk cohorts and that may have 
influenced clinician behaviour. It is uncertain why diabetic 
patients, another high risk cohort, were less likely to be 
treated in accordance with guidelines. 
Quality improvement strategies such as continued 
education, integrated care, and pre-discharge checklists 
have been shown to enhance compliance with evidence-
based guidelines.8,27,28 Addressing the issue of suboptimal 
ACEI/ARB and beta-blocker prescribing, which is also 
common in Europe, North America, and the Middle East, 
seems key.5,11,15,16 In other countries, pharmacists working 
in primary and secondary care have been shown to be 
effective in improving the prescribing rates and dosing of 
secondary prevention cardiac medications.29,30 In Iraq, 
clinical pharmacists are not usually involved in the coronary 
care unit, as their role is limited to dispensing 
medications.31 Thus, the incorporation of pharmacists into 
the multidisciplinary team to improve the prescribing and 
dosing of secondary prevention medications may improve 
the quality of care for these patients.29,30 In addition, 
pharmacists can educate patients and caregivers as per the 
guidelines recommendations about drug therapy, 
discussing indications, possible side effects, drug-drug or 
food-drug interactions, and monitoring.13,14,32 
Iraq has a workforce of over 11,000 practicing pharmacists, 
most of whom work in state-funded primary and secondary 
care or privately owned community pharmacies, where 
services centre on traditional dispensing and distribution of 
medicines.31 The opportunities for Iraqi pharmacists to 
assume clinical roles have grown over the last 20 years.31 
Specialisation, involving post-graduate qualifications and 
board certification, is becoming commonplace.31 A future 
opportunity, therefore, exists to develop extended roles in 
specialities such as cardiology, as seen in the US and the 
UK.32,33 Government funding models and legislation 
changes many ultimately be required to facilitate this.31 
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Future studies in Iraq should assess barriers and variations 
to optimal prescribing of ACEI/ARBs and beta-blockers in 
clinical practice using quantitative and qualitative methods. 
These studies should also consider assessing and evaluating 
clinical pharmacist interventions in optimising patient care 
to support future professional and service developments. 
 
CONCLUSIONS 
Approximately one in two patients received the 
recommended secondary prevention medicines. However, 
only a few patients were prescribed target doses of 
ACEI/ARBs and/or beta-blockers. Quality improvement 
strategies and further research should be implemented to 
optimise prescribing. This may include greater involvement 
of pharmacists within the cardiology multidisciplinary team. 
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